Low LATS2 mRNA level can predict favorable response to epirubicin plus cyclophosphamide, but not to docetaxel, in breast cancers
2007; Springer Science+Business Media; Volume: 133; Issue: 8 Linguagem: Inglês
10.1007/s00432-007-0194-0
ISSN1432-1335
AutoresYuri Takahashi, Yasuo Miyoshi, Koji Morimoto, Tetsuya Taguchi, Yasuhiro Tamaki, Shinzaburo Noguchi,
Tópico(s)Cancer-related Molecular Pathways
Referência(s)